Shares in Telix Pharmaceutical climbed in morning trade after the company reported positive results from a global phase 3 trial of its advanced prostate cancer treatment, TLX591.

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial ...

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

Fans of Emmerdale have been left "crying my eyes out" after Cain Dingle's poignant cancer revelation. ITV soap fans will recall that Cain (Jeff Hordley) was shot by John Sugden (Oliver Farnworth) in ...

Researchers have found in a new study that among men with prostate cancer undergoing androgen deprivation therapy, use of oxybutynin 5 mg twice daily significantly reduced the frequency ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit desired safety and dosage goals.

Former ET co-host John Tesh revealed he that he far exceeded the wildest expectations of doctors who diagnosed him with ...

In a second EU approval today, Johnson & Johnson got a green light for Akeega (niraparib and abiraterone acetate) for the ...

Cancer Research UK data shows death rates have fallen 11% in the last decade overall with significant falls in cancers such as breast cancer and cervical cancer ...

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.